Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Leroy Monroe Parker, M.D.


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Mayer EL, Gropper AB, Harris L, Gold JM, Parker L, Kuter I, Come S, Najita JS, Guo H, Winer EP, Burstein HJ. Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer. Clin Breast Cancer. 2015 Feb; 15(1):24-30. PMID: 25205424.
    Citations: 5     Fields:    Translation:HumansCells
  2. Chen WY, Giobbie-Hurder A, Gantman K, Savoie J, Scheib R, Parker LM, Schernhammer ES. A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes. Breast Cancer Res Treat. 2014 Jun; 145(2):381-8. PMID: 24718775.
    Citations: 36     Fields:    Translation:Humans
  3. Campos SM, Berlin ST, Parker LM, Chen WY, Bunnell CA, Atkinson T, Lee J, Matulonis U, Hirsch MS, Harris L, Krasner CN. Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. Int J Clin Oncol. 2010 Aug; 15(4):390-8. PMID: 20405155.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  4. Snyder BD, Cordio MA, Nazarian A, Kwak SD, Chang DJ, Entezari V, Zurakowski D, Parker LM. Noninvasive Prediction of Fracture Risk in Patients with Metastatic Cancer to the Spine. Clin Cancer Res. 2009 Dec 15; 15(24):7676-7683. PMID: 19996215.
    Citations: 27     Fields:    
  5. Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos SM, Shulman LN, Harris LN, Gelman R, Winer EP. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res. 2008 Dec 01; 14(23):7871-7. PMID: 19047116.
    Citations: 46     Fields:    Translation:HumansCTClinical Trials
  6. Lin NU, Parker LM, Come SE, Burstein HJ, Haldoupis M, Ryabin N, Gelman R, Winer EP, Shulman LN. Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest New Drugs. 2007 Aug; 25(4):369-75. PMID: 17345004.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  7. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007 Mar; 11(3):259-73. PMID: 17349583.
    Citations: 622     Fields:    Translation:HumansCells
  8. Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005 Nov 20; 23(33):8340-7. PMID: 16293865.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  9. Burstein HJ, Bellon JR, Galper S, Lu HM, Kuter I, Taghian AG, Wong J, Gelman R, Bunnell CA, Parker LM, Garber JE, Winer EP, Harris JR, Powell SN. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. Int J Radiat Oncol Biol Phys. 2006 Feb 01; 64(2):496-504. PMID: 16243442.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  10. Vansonnenberg E, Shankar S, Parker L, Cheung L, Morrison PR, Silverman SG, Igelhart D. Palliative radiofrequency ablation of a fungating, symptomatic breast lesion. AJR Am J Roentgenol. 2005 Mar; 184(3 Suppl):S126-8. PMID: 15728004.
    Citations:    Fields:    Translation:Humans
  11. Robertson JF, Erikstein B, Osborne KC, Pippen J, Come SE, Parker LM, Gertler S, Harrison MP, Clarke DA. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer. Clin Pharmacokinet. 2004; 43(8):529-38. PMID: 15170367.
    Citations: 18     Fields:    Translation:HumansCTClinical Trials
  12. Piccart M, Parker LM, Pritchard KI. Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer. Ann Oncol. 2003 Jul; 14(7):1017-25. PMID: 12853342.
    Citations: 5     Fields:    Translation:HumansCells
  13. Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 2003 Jan 01; 21(1):46-53. PMID: 12506169.
    Citations: 62     Fields:    Translation:HumansCTClinical Trials
  14. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002 Aug 15; 20(16):3386-95. PMID: 12177098.
    Citations: 118     Fields:    Translation:HumansCTClinical Trials
  15. Griffiths CT, Parker LM, Lee S, Finkler NJ. The effect of residual mass size on response to chemotherapy after surgical cytoreduction for advanced ovarian cancer: long-term results. Int J Gynecol Cancer. 2002 Jul-Aug; 12(4):323-31. PMID: 12144679.
    Citations: 7     Fields:    Translation:Humans
  16. Parker LM. Sequencing of hormonal therapy in postmenopausal women with metastatic breast cancer. Clin Ther. 2002; 24 Suppl C:C43-57. PMID: 12117075.
    Citations: 1     Fields:    Translation:Humans
  17. Torosian M, O'Shaughnessy J, Parker LM, Vogel C. Fulvestrant: clinical application of an estrogen receptor downregulator. Clin Ther. 2002; 24 Suppl A:A31-40. PMID: 11911508.
    Citations:    Fields:    Translation:HumansCells
  18. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001 May 15; 19(10):2722-30. PMID: 11352965.
    Citations: 58     Fields:    Translation:HumansCTClinical Trials
  19. Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000 Mar; 18(6):1212-9. PMID: 10715290.
    Citations: 43     Fields:    Translation:HumansCTClinical Trials
  20. Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Marcom PK, Matulonis UA, Parker LM, Harris LN, Winer EP. Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol. 1999 Sep; 10(9):1113-6. PMID: 10572612.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  21. Parker LM, Bornstein BA. Endocrine and cytotoxic therapies for the management of advanced local breast cancer. Current clinical investigation. Surg Oncol Clin N Am. 1995 Oct; 4(4):779-90. PMID: 8535910.
    Citations:    Fields:    Translation:Humans
  22. Lamb CC, Eberlein TJ, Parker LM, Silver B, Harris JR. Results of radical radiotherapy for inflammatory breast cancer. Am J Surg. 1991 Sep; 162(3):236-42. PMID: 1928584.
    Citations: 3     Fields:    Translation:Humans
  23. Parker LM, Boyages J, Eberlein TJ. Inflammatory Breast Cancer. in Harris JR, Hellman S, Henderson IC, Kinne DW ,editors, Breast Diseases. 1991; 775-82.
  24. Henderson IC, Hayes DF, Parker LM, Love S, Garber JE, Recht A, Breitmeyer JB, Harris JR, Canellos GP. Adjuvant systemic therapy for patients with node-negative tumors. Cancer. 1990 May 01; 65(9 Suppl):2132-47. PMID: 2183925.
    Citations: 2     Fields:    Translation:Humans
  25. Parker LM. Doctor-patient communication and ethical issues. J Clin Oncol. 1989 Sep; 7(9):1182-3. PMID: 2671278.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  26. Krag KJ, Canellos GP, Griffiths CT, Knapp RC, Parker LM, Welch WR, Klatt M, Andersen J. Predictive factors for long-term survival in patients with advanced ovarian cancer. Gynecol Oncol. 1989 Jul; 34(1):88-93. PMID: 2525510.
    Citations: 4     Fields:    Translation:Humans
  27. Sheldon T, Hayes DF, Cady B, Parker L, Osteen R, Silver B, Recht A, Come S, Henderson IC, Harris JR. Primary radiation therapy for locally advanced breast cancer. Cancer. 1987 Sep 15; 60(6):1219-25. PMID: 3621108.
    Citations: 9     Fields:    Translation:HumansPHPublic Health
  28. Sheldon TA, Parker LM, Cady B. Management of Locally Advanced Breast Cancer. in Harris JR, Hellman S, Henderson IC, Kinne DW, editors, Breast Diseases. 1987; 563-70.
  29. Parker LM, Sheldon TA, Cady B. Inflammatory Breast Cancer. in Harris JR, Hellman S, Henderson IC, Kinne DW, editors, Breast Diseases. 1987; 57077.
  30. Upchurch KS, Parker LM, Scully RE, Krane SM. Differential cyclic AMP responses to calcitonin among human ovarian carcinoma cell lines: a calcitonin-responsive line derived from a rare tumor type. J Bone Miner Res. 1986 Jun; 1(3):299-304. PMID: 2845729.
    Citations: 8     Fields:    Translation:HumansCells
  31. Griffiths CT, Parker LM. Cancer of the Ovary. in Knapp RC, Berkowitz RS, editors Gynecologic Oncology. 1986; 313-77.
  32. Parker LM, Burstein NA. Overall Principles of Cancer Management: Hormone Therapy. Cancer Manual. 1986; 82-5.
  33. Parker LM, Griffiths CT, Knapp RC. Cancer of the Female Genital Tract. Cancer Manual. 1986; 222-40.
  34. Karp DD, Parker LM, Binder N, Tantravahi R, Smith BR, Ervin TJ, Canellos GP. Treatment of the blastic transformation of chronic granulocytic leukemia using high dose BCNU chemotherapy and cryopreserved autologous peripheral blood stem cells. Am J Hematol. 1985 Mar; 18(3):243-9. PMID: 2858155.
    Citations:    Fields:    Translation:HumansCells
  35. Berek JS, Knapp RC, Hacker NF, Lichtenstein A, Jung T, Spina C, Obrist R, Griffiths CT, Berkowitz R, Parker L, Lagasse LD, Zighelboim J, Bast RC. Intraperitoneal chemotherapy of epithelial ovarian carcinoma with Corynebacterium parvum. Am J Obst Gynecol. 1985; 152:1003-10.
  36. Rado TA, Bollekens J, St Laurent G, Parker L, Benz EJ. Lactoferrin biosynthesis during granulocytopoiesis. Blood. 1984 Nov; 64(5):1103-9. PMID: 6593100.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  37. Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Knapp RC. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983 Oct 13; 309(15):883-7. PMID: 6310399.
    Citations: 369     Fields:    Translation:Humans
  38. Takvorian T, Parker LM, Hochberg FH, Canellos GP. Autologous bone-marrow transplantation: host effects of high-dose BCNU. J Clin Oncol. 1983 Oct; 1(10):610-20. PMID: 6366127.
    Citations: 10     Fields:    Translation:Humans
  39. Parker LM. Leukemia after treatment of ovarian cancer with alkylating agents. N Engl J Med. 1983 Jun 09; 308(23):1422. PMID: 6843637.
    Citations:    Fields:    Translation:Humans
  40. Bast RC, Berek JS, Obrist R, Griffiths CT, Berkowitz RS, Hacker NF, Parker L, Lagasse LD, Knapp RC. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum. Cancer Res. 1983 Mar; 43(3):1395-401. PMID: 6825108.
    Citations: 10     Fields:    Translation:HumansCells
  41. Wu YJ, Parker LM, Binder NE, Beckett MA, Sinard JH, Griffiths CT, Rheinwald JG. The mesothelial keratins: a new family of cytoskeletal proteins identified in cultured mesothelial cells and nonkeratinizing epithelia. Cell. 1982 Dec; 31(3 Pt 2):693-703. PMID: 6186388.
    Citations: 144     Fields:    Translation:HumansCells
  42. Parker LM, Lipton JM, Binder N, Crawford EL, Kudisch M, Levin MJ. Effect of acyclovir and interferon on human hematopoietic progenitor cells. Antimicrob Agents Chemother. 1982 Jan; 21(1):146-50. PMID: 6177284.
    Citations: 5     Fields:    Translation:HumansCells
  43. Knapp RC, Cramer D, Easterday CL, Goldstein DP, Leavitt T, Marchant DJ, Nelson JH, Parker LM. Gynecologic Cancer. Cancer Manual. 1982; 212-31.
  44. Antman KH, Parker LM, Goldstein JD, Skarin AT, D'Orsi CJ. Acute renal failure following intravenous pyelography (IVP) in a patient with diffuse hypergammaglobulinemia: a case report. Med Pediatr Oncol. 1982; 10(3):289-94. PMID: 7045616.
    Citations:    Fields:    Translation:Humans
  45. Greenberg HM, Newburger PE, Parker LM, Novak T, Greenberger JS. Human granulocytes generated in continuous bone marrow culture are physiologically normal. Blood. 1981 Oct; 58(4):724-32. PMID: 7272503.
    Citations: 5     Fields:    Translation:HumansCells
  46. Parker LM, Binder N, Gelman R, Richman CM, Weiner RS, Yankee RA. Prolonged cryopreservation of human bone marrow. Transplantation. 1981 Jun; 31(6):454-7. PMID: 7256827.
    Citations: 1     Fields:    Translation:HumansCells
  47. Hochberg FH, Parker LM, Takvorian T, Canellos GP, Zervas NT. High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme. J Neurosurg. 1981 Apr; 54(4):455-60. PMID: 6259300.
    Citations: 24     Fields:    Translation:Humans
  48. Greenberg HM, Parker LM, Newburger PE, Said J, Cohen GI, Greenberger JS. Corticosteroid dependence of continuous hemopoiesis in vitro with murine or human bone marrow. Haematol Blood Transfus. 1981; 26:289-93. PMID: 7319292.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  49. Pesando JM, Come SE, Stark J, Parker LM, Griffiths CT, Canellos GP. cis-Diamminedichloroplatinum(II) therapy for advanced ovarian cancer. Cancer Treat Rep. 1980 Oct-Nov; 64(10-11):1147-8. PMID: 7193089.
    Citations: 2     Fields:    Translation:Humans
  50. Parker LM, Griffiths CT, Yankee RA, Canellos GP, Gelman R, Knapp RC, Richman CM, Tobias JS, Weiner RS, Frei E. Combination chemotherapy with adriamycin-cyclophosphamide for advanced ovarian carcinoma. Cancer. 1980 Aug 15; 46(4):669-74. PMID: 7397632.
    Citations: 5     Fields:    Translation:Humans
  51. Kufe DW, Beardsley P, Karp D, Parker L, Rosowsky A, Canellos G, Frei E. High-dose thymidine infusions in patients with leukemia and lymphoma. Blood. 1980 Apr; 55(4):580-9. PMID: 6965595.
    Citations: 11     Fields:    Translation:HumansCells
  52. Frei E, Blum RH, Pitman SW, Kirkwood JM, Henderson IC, Skarin AT, Mayer RJ, Bast RC, Garnick MB, Parker LM, Canellos GP. High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med. 1980 Mar; 68(3):370-6. PMID: 6965819.
    Citations: 23     Fields:    Translation:Humans
  53. Garnick MB, Blum RH, Canellos GP, Mayer RJ, Parker L, Skarin AT, Li FP, Henderson IC, Frei E. Phase I trial of bruceantin. Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):1929-32. PMID: 526926.
    Citations: 4     Fields:    Translation:Humans
  54. Lowenthal IS, Parker LM, Greenblatt DJ, Brown BL, Samy TS. Pharmacokinetic analysis of neocarzinostatin in normal and tumor-bearing rodents. Cancer Res. 1979 May; 39(5):1547-51. PMID: 154972.
    Citations: 1     Fields:    Translation:Animals
  55. Griffiths CT, Parker LM, Fuller AF. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep. 1979 Feb; 63(2):235-40. PMID: 445502.
    Citations: 29     Fields:    Translation:Humans
  56. Parker LM, Griffiths CT, Yankee RA, Knapp RC, Canellos GP. High-dose methotrexate with leucovorin rescue in ovarian cancer: a phase II study. Cancer Treat Rep. 1979 Feb; 63(2):275-9. PMID: 312692.
    Citations: 3     Fields:    Translation:Humans
  57. Greenberger JS, Sakakeeny M, Parker LM. In vitro proliferation of hemopoietic stem cells in long-term marrow cultures: principles in mouse applied to man. Exp Hematol. 1979; 7 Suppl 5:135-48. PMID: 263239.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  58. Weiner RS, Richman CM, Yankee RA, Parker L. Clinical results of autotransplantation after nitrosourea therapy. Exp Hematol. 1979; 7 Suppl 5:384-8. PMID: 400701.
    Citations:    Fields:    Translation:Humans
  59. Cotter SM, Parker LM. High-dose methotrexate and leucovorin rescue in dogs with osteogenic sarcoma. Am J Vet Res. 1978 Dec; 39(12):1943-5. PMID: 312044.
    Citations: 2     Fields:    Translation:Animals
  60. Bern MM, McDermott W, Cady B, Oberfield RA, Trey C, Clouse ME, Tullis JL, Parker LM. Intraaterial hepatic infusion and intravenous adriamycin for treatment of hepatocellular carcinoma: a clinical and pharmacology report. Cancer. 1978 Aug; 42(2):399-405. PMID: 209882.
    Citations: 15     Fields:    Translation:Humans
  61. Blum RH, Wittenberg BK, Canellos GP, Mayer RJ, Skarin AT, Henderson IC, Parker LM, Frei E. A therapeutic trial of maytansine. Cancer Clin Trials. 1978; 1(2):113-7. PMID: 757139.
    Citations: 9     Fields:    Translation:Humans
  62. Parker LM, Hirst M, Israel M. N-trifluoroacetyladriamycin-14-valerate: additional mouse antitumor and toxicity studies. Cancer Treat Rep. 1978 Jan; 62(1):119-27. PMID: 272230.
    Citations: 6     Fields:    Translation:Animals
  63. Tobias JS, Weiner RS, Giffiths CT, Richman CM, Parker LM, Yankee RA. Cryopreserved autologous marrow infusion following high dose cancer chemotherapy. Eur J Cancer. 1977 Mar 29; 13(3):269-77. PMID: 324770.
    Citations: 6     Fields:    Translation:HumansCells
  64. Curt GA, Tobias JS, Kramer RA, Rosowsky A, Parker LM, Tattersall MH. Inhibition of nucleic acid synthesis by the di-n-butyl ester of methotrexate. Biochem Pharmacol. 1976 Sep 01; 25(17):1943-6. PMID: 985531.
    Citations: 4     Fields:    Translation:Cells
  65. Tobias JS, Parker LM, Tattersall MH, Frei E. Adriamycin/cyclophosphamide and adriamycin/melphalan in advanced L1210 leukaemia. Br J Cancer. 1975 Aug; 32(2):199-207. PMID: 1212350.
    Citations: 2     Fields:    Translation:Animals
  66. Tattersall MHN, Parker LM, Pitman SW, Frei E. The clinical pharmacology of high-dose methotrexate. Cancer Chemotherapy Reports. 1975; 6:25-29.
  67. Frei E, Jaffe N, Tattersall MHN, Pitman SW, Parker LM. New approaches to methotrexate treatment. Seminars in Medicine of the Beth Israel Hospital. N Eng J Medicine. 1975; 298:846-51.
  68. Pitman SW, Parker LM, Tattersall MHN, Frei E. Clinical trial of high-dose methorexate-citrovorum factor: toxicologic and therapeutic considerations. Cancer Chemotherapy Reports. 1975; 5:43-49.
  69. Gelfand MC, Parker LM, Steinberg AD. Mechanism of allograft rejection in New Zealand mice. II. Role of a serum factor. J Immunol. 1974 Jul; 113(1):1-8. PMID: 4598887.
    Citations: 5     Fields:    Translation:AnimalsCells
  70. Parker LM, Chused TM, Steinberg AD. Immunofluorescence studies on thymocytotoxic antibody from New Zealand Black mice. J Immunol. 1974 Jan; 112(1):285-92. PMID: 4590823.
    Citations: 16     Fields:    Translation:AnimalsCells
  71. Chused TM, Steinberg AD, Parker LM. Enhanced antibody response of mice to polyinosinic-polycytidylic acid by antithymocyte serum and its age-dependent loss in NZB-W mice. J Immunol. 1973 Jul; 111(1):52-7. PMID: 4541325.
    Citations: 11     Fields:    Translation:AnimalsCells
  72. Parker LM, Steinberg AD. The antibody response to polyinosinic polycytidylic acid. J Immunol. 1973 Mar; 110(3):742-51. PMID: 4120225.
    Citations: 8     Fields:    Translation:Animals
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Parker's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (330)
Co-Authors (49)
Similar People (60)
Same Department 
Physical Neighbors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.